Genes
ALK, AKT1, AR, ATM, BAP1, BRAF, BRCA1, BRCA2, CDKN2A, CCND1, CREBBP, EGFR, ERBB2, ERBB3, ERBB4, FANCA, FBXW7, FGFR1, FGFR2, FGFR3, HRAS, KDM6A, KMT2A, KMT2C, KMT2D, KRAS, MAP2K1, NF1, NRAS, PIK3CA, PTEN, RB1, RET, SMARCA4, STAG2, TERT, TP53.

Disease:
urothelial and bladder cancers

The OncoSwift® Bladder Comprehensive Panel performs broad genomic profiling of bladder and urothelial carcinomas, detecting mutations, copy number changes, and fusions in key oncogenic pathways. This assay provides diagnostic, prognostic, and therapeutic insights, supporting selection of targeted and immunotherapy options.

Preparation:
PB

Collection:
Two tubes of peripheral blood (10mL/tube) are collected in PAXgene Blood ccfDNA tube

Stability:
7 to 10 days at room temperature

Unacceptable Conditions:
Specimen submitted is not in the PAXgene Blood ccfDNA Tubes or n the PAXgene Blood ccfDNA tube after expired date. Insufficient specimen (less than 10 mL whole blood/tube). Specimen is leaking from the collection tube, or the glass tube is broken. Gross hemolysis. Bacterial overgrowth Submitted with incomplete requisition form (unless a requisition is subsequently sent). Unlabeled or improperly labeled specimens, without contact information or when failing to reach the ordering physician for clarification. cfDNA shipped in inappropriate temperature .